Compare
The details that actually shape the buying decision.
Evidence, risk, regulatory flags, cost, and vendor coverage — side by side, without affiliate spin.
01· Subject
GHRP-2
GH secretagogue studied in human stimulation tests with documented endocrine spillover effects.
Tier Bhigh risk
02· Subject
CJC-1295
Long-acting GHRH analogue studied in human trials for sustained GH/IGF-1 elevation.
Tier Bhigh risk
01 · At a glance
| Decision factor | GHRP-2 | CJC-1295 | Sermorelin |
|---|---|---|---|
| Primary fit | muscle growth & strength and fat loss & metabolism comparisons | muscle growth & strength and fat loss & metabolism comparisons | gh axis optimization research where you want a clear starting point |
| Evidence | Tier B | Tier B | Tier B |
| Risk | high | high | medium |
| Experience level | intermediate | intermediate | intermediate |
| Budget tier | mid | mid | mid |
| Administration route | intravenous, subcutaneous | subcutaneous | subcutaneous |
02 · Use case & timing
| Decision factor | GHRP-2 | CJC-1295 | Sermorelin |
|---|---|---|---|
| Goal fit | Muscle Growth & Strength, Fat Loss & Metabolism, GH Axis Optimization | Muscle Growth & Strength, Fat Loss & Metabolism, GH Axis Optimization | GH Axis Optimization |
| What users compare it for | GH-axis stimulation; diagnostic use in some clinical settings. | Sustained GH and IGF-1 elevation; body composition modulation (long-horizon, not well-established for consumer outcomes). | GH axis stimulation; growth/body composition changes over months. |
| Onset timeline | Acute hormone response within minutes to hours in stimulation tests. | Biomarker effects persist multiple days; IGF-1 elevations up to ~2 weeks after single dose. | GH secretion changes occur acutely; body composition endpoints are months-horizon. |
| Main tradeoff | Evidence is stronger than most compounds in this category, but route, side effects, and vendor fit still matter. | Evidence is stronger than most compounds in this category, but route, side effects, and vendor fit still matter. | Evidence is stronger than most compounds in this category, but route, side effects, and vendor fit still matter. |
03 · Safety & restrictions
| Decision factor | GHRP-2 | CJC-1295 | Sermorelin |
|---|---|---|---|
| Adverse effects | Endocrine spillover (ACTH, cortisol, prolactin); glucose metabolism concerns. | Injection-site reactions, headache, diarrhea, flushing, transient hypotension at higher doses. | Glucose intolerance risk; theoretical neoplasia concerns with sustained IGF-1 elevation. |
| Contraindications | No formal label (not approved for consumer use). | GH-axis stimulation risks: glucose intolerance, theoretical neoplasia concerns with elevated IGF-1. | Active malignancy (by analogy to tesamorelin class warnings). |
| Interaction notes | Endocrine spillover risks; avoid 'safe GH boost' framing. | Monitor insulin/glucose sensitivity, thyroid axis, and cortisol/prolactin. Trials report no significant cortisol/prolactin/TSH/LH increases at 60 µg/kg single dose. | Unknown interaction profile outside supervised settings. |
| Regulatory status | Not approved | Not approved | Not approved |
| FDA flag | FDA status unclear | FDA compounding caution | FDA status unclear |
| WADA status | WADA S2 | WADA S2 | WADA S2 |
04 · Age & monitoring
| Decision factor | GHRP-2 | CJC-1295 | Sermorelin |
|---|---|---|---|
| Supported age ranges | No age guidance yet | 25-34, 35-44, 45-54 | No age guidance yet |
| Life-stage note | Not yet documented | Midlife is where GH-restoration framing is most often used, but evidence and long-term safety remain limited. | Not yet documented |
| Monitoring burden | Not specified | high | Not specified |
| Follow-up cadence | Not yet documented | Reassess at startup and then roughly every few months if continuing. | Not yet documented |
05 · Cost & sourcing
| Decision factor | GHRP-2 | CJC-1295 | Sermorelin |
|---|---|---|---|
| Typical cycle cost | No reliable estimate yet | $143.98 | $480.00 |
| Estimated monthly cost | No reliable estimate yet | $47.99 | $160.00 |
| Cost confidence | No estimate | High confidence | High confidence |
06 · Before you buy
| Decision factor | GHRP-2 | CJC-1295 | Sermorelin |
|---|---|---|---|
| Tracked vendor listings | 0 listings | 3 listings | 1 listing |
| Sourcing note | No tracked product page yet, so sourcing takes more manual review. | At least one listing is a blend rather than a clean standalone product, so review the product page carefully. | Product format varies by listing, so double-check route, concentration, and presentation. |
| Stack-friendly? | Usually stack-friendly | Usually stack-friendly | Usually stack-friendly |
Still deciding
Get a plan tailored to you.
Side-by-side narrows the field. The quiz factors in your goal, experience, and risk tolerance to surface a starting compound and dosing range.